117 related articles for article (PubMed ID: 2305719)
1. Phase II trial of 10-Edam in patients with advanced colorectal carcinoma.
Kemeny N; Israel K; O'Hehir M
Am J Clin Oncol; 1990 Feb; 13(1):42-4. PubMed ID: 2305719
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer.
Lee JS; Libshitz HI; Murphy WK; Jeffries D; Hong WK
Invest New Drugs; 1990 Aug; 8(3):299-304. PubMed ID: 2177045
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of 10-deaza-aminopterin in patients with advanced colorectal cancer.
Cheng EW; Currie VE; Yagoda A
Am J Clin Oncol; 1983 Aug; 6(4):469-71. PubMed ID: 6869317
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
Shum KY; Kris MG; Gralla RJ; Burke MT; Marks LD; Heelan RT
J Clin Oncol; 1988 Mar; 6(3):446-50. PubMed ID: 2832548
[TBL] [Abstract][Full Text] [Related]
5. Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.
Verweij J; Schornagel J; de Mulder P; Henzen-Logmans S; Cognetti F; Clavel M; Vermorken J
Cancer; 1990 Nov; 66(9):1910-3. PubMed ID: 2224785
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Kris MG; Kinahan JJ; Gralla RJ; Fanucchi MP; Wertheim MS; O'Connell JP; Marks LD; Williams L; Farag F; Young CW
Cancer Res; 1988 Oct; 48(19):5573-9. PubMed ID: 3416310
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma.
Pazdur R; Moore DF; Bready B; Giannone L; Maldonado A; Lin YG; Fueger RH; Winn RJ; Levin B
Ann Oncol; 1994 Sep; 5(7):646-8. PubMed ID: 7527654
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.
Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; Clavel M; Kirkpatrick A
Ann Oncol; 1992 Mar; 3(3):223-6. PubMed ID: 1586620
[TBL] [Abstract][Full Text] [Related]
10. Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts.
Brown DH; Braakhuis BJ; van Dongen GA; van Walsum M; Bagnay M; Snow GB
Anticancer Res; 1989; 9(6):1549-52. PubMed ID: 2627109
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of 10-EDAM in advanced soft tissue sarcoma. A study of the Canadian Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group.
Knowling M; Bramwell V; Eisenhauer E; Boos G; Bodurtha A; Quirt I
Ann Oncol; 1994 Oct; 5(8):766-8. PubMed ID: 7826912
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.
Schornagel JH; van der Vegt S; Verweij J; de Graeff A; Dullemond-Westland A; van Deijk WA; ten Bokkel Huinink WW
Ann Oncol; 1992 Jul; 3(7):549-52. PubMed ID: 1498076
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 10-deazaaminopterin for advanced hypernephroma.
Scher HI; Yagoda A; Ahmed T; Hollander P; Watson RC
Anticancer Res; 1984; 4(6):409-10. PubMed ID: 6517533
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of 10 deaza-aminopterin in patients with bladder cancer.
Ahmed T; Yagoda A; Scher HI; Sternberg C; Watson RC
Invest New Drugs; 1986; 4(2):171-4. PubMed ID: 3733377
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Vandenberg TA; Pritchard KI; Eisenhauer EA; Trudeau ME; Norris BD; Lopez P; Verma SS; Buckman RA; Muldal A
J Clin Oncol; 1993 Jul; 11(7):1241-4. PubMed ID: 8315420
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.
Verma S; Quirt IC; Eisenhauer EA; Iscoe NA; Young VJ; Bodurtha AJ; Davidson J
Ann Oncol; 1993 Mar; 4(3):254-5. PubMed ID: 8471559
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy.
Green MD; Sherman P; Zalcberg J
Invest New Drugs; 1992 Apr; 10(1):31-4. PubMed ID: 1607252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
